Aragon's Series D Adds $50M To Advance ARN-509 in CRPC
Aragon Pharmaceuticals Inc. parlayed its successful Phase II results in prostate cancer to a new financing round worth $50 million supported by existing investors and led by new investor venBio. The funds will support advancement of ARN-509 in castration-resistant prostate cancer (CRPC).
Aragon has raised a total of $88 million in 2012, having closed a $42 million Series C in March. (See BioWorld Today, March 6, 2012.)
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST